We are a leading provider of commercial manufacturing outsourcing services ("CMO") and outsourced pharmaceutical development services ("PDS") to the global pharmaceutical industry. We believe we are the world's second-largest CMO provider and the world's largest PDS provider based on calendar year 2012 revenues provided by PharmSource, a provider of pharmaceutical outsourcing business information. We offer a wide range of services throughout the lifecycle of a pharmaceutical molecule, from early development, through late development to commercial manufacturing including lifecycle management services. During the fiscal year ended October 31, 2013 ("fiscal 2013"), we provided services to approximately 533 customers throughout the world including 19 of the world's 20 largest pharmaceutical companies, eight of the world's 10 largest biotechnology companies and eight of the world's 10 largest specialty pharmaceutical companies. In fiscal 2013, we manufactured 12 of the top 100 selling drug compounds in the world based on revenues for the products reported by Evaluate Pharma, a provider of pharmaceutical industry data, and our products were distributed in over 70 countries. We are also currently developing 12 of the top 100 development stage drugs in the world on behalf of our customers based on potential revenues for the products reported by Evaluate Pharma. Our CMO business focuses primarily on prescription products in a wide variety of solid and sterile dosage forms. We have also developed a range of specialized capabilities in high potency, controlled substances, modified release products, and softgel technologies. With the Banner Acquisition, we expanded our service offering to include the development, licensing and commercialization of proprietary prescription, over the counter and nutritional products while leveraging the combined expertise and capabilities of Banner and Patheon. Our PDS business provides a broad range of development services including finished dosage formulation across approximately 40 dosage forms, early development services, analytical services, formulation expertise and life cycle management. We have established our position as a market leader by leveraging our scale, global reach, specialized capabilities, broad service offerings, scientific expertise and track record of product quality and regulatory compliance to provide competitive and cost-effective solutions to our customers.
Company profile
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
SC TO-C
Information about tender offer
15 May 17
15-12G
Securities registration termination
11 Mar 14
8-K
Patheon Completes Plan of Arrangement
11 Mar 14
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Mar 14
SC 13E3/A
Going private transaction (amended)
11 Mar 14
8-K
Patheon Inc. Announces Final Court Approval of Arrangement
10 Mar 14
8-K
Patheon Shareholders Approve Plan of Arrangement
6 Mar 14
8-K
Patheon Reports Preliminary Unaudited First Quarter Fiscal 2014 Results
6 Mar 14
EFFECT
Notice of effectiveness
4 Mar 14
POS AM
Prospectus update (post-effective amendment)
3 Mar 14
Latest ownership filings